Is participation in this Tampa clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

I cannot determine the primary medical condition from the provided information. The study title only mentions "ST-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (ST-067, Obinutuzumab, and pembrolizumab) rather than medical conditions. The brief summary field appears to be incomplete. Without information about the actual disease or condition being treated, I cannot extract a patient-facing medical condition. Clinical Trial in Tampa, FL

Q: Is NCT04787042 recruiting in Tampa, FL?

Yes, NCT04787042 is currently recruiting participants at its Tampa, FL location. This i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. clinical trial is actively enrolling qualified participants.

Q: How do I join the i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. clinical trial in Tampa?

To join this clinical trial in Tampa, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Access cutting-edge i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. treatment through this phase 1/2 clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Inclusion Criteria

Male and female patients aged ≥18 years

Must provide written informed consent and any authorizations required by local law

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Have histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumor For Phase 1a, the following solid tumors are allowed: Melanoma, Merkel cell, RCC, urothelial, NSCLC,TNBC, SCCHN, microsatellite instability high, high tumor mutation burden (Hi TMB) or mismatch repair deficient, gastric, cervical, endometrial, cutaneous squamous, small cell lung, esophageal, hepatocellular carcinoma and platinum resistant ovarian cancer.

For patients who have developed disease progression through standard therapy, or

For patients whom standard of care therapy that prolongs survival is unavailable or unsuitable (according to the investigator and after consultation with the Medical Monitor) For Phase 1 combination therapy dose escalation, the following solid tumors are allowed: Melanoma, Merkel cell, RCC, urothelial, NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions), TNBC, SCCHN, MSI-Hi tumors, Hi TMB or mismatch repair deficient, gastric, cervical, endometrial, cutaneous squamous, small cell lung, esophageal, and HCC

TNBC is diagnosed in a tumor which does not express estrogen receptor or progesterone receptor, is not human epidermal growth factor receptor 2 (HER2) 3+ on IHC or is negative by fluorescence in situ hybridization (FISH).

MSI high tumor should have mutations in 30% or more microsatellites by PCR or be negative for MSH1/2/6 or PMS-2 by IHC.

Hi-TMB high tumor has 10 mut/Mb or greater calculated from whole genome sequencing or whole exome sequencing For Phase 2, the following solid tumors are allowed: Melanoma, RCC, TNBC, NSCLC, SCCHN, and MSI-Hi tumors

Has at least 1 measurable lesion per RECIST 1.1 criteria which has not been biopsied or received prior irradiation

Has an accessible tumor for biopsy pre- and on-treatment (mandatory).

Exclusion Criteria

History of another malignancy

Known symptomatic brain metastases requiring \>10 mg/day of prednisolone or equivalent

Significant cardiovascular disease (MI, thrombotic events,) within 6 months prior to study treatmentSignificant ECG abnormalities (Phase 1a and 2 monotherapy only) including unstable cardiac arrhythmia requiring medication, second-degree atrioventricular block type II, third degree AV

Any degree of respiratory compromise (from either malignant or non-malignant disease)

Evidence of an ongoing systemic bacterial, fungal, or viral infection

Has received a live vaccine within 30 days

Major surgery within 4 weeks

Prior solid organ or bone marrow progenitor cell transplantation

Prior high dose chemotherapy requiring stem cell rescue

History of active autoimmune disorders

Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids.

Treatment with an approved, systemic anticancer therapy or an investigational agent within 4 weeks of Day 1

A positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral test within 28 days prior to dosing, unless there is Investigator-confirmed clinical recovery on or before C1D1

Subjects with adrenal insufficiency

Subjects with any chemistry or hematology laboratory values that are ≥Grade 2 Additional exclusion criteria for Phase 1 combination therapy only:

Presence of known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.

Prior radiotherapy within 2 weeks of start of study treatment or history of radiation pneumonitis.

Presence of an active documented autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine or insulin) is not considered a form of systemic treatment and is allowed. Subjects may use topical and/or inhaled corticosteroids. However, subjects with adrenal insufficiency on replacement doses of steroids are not allowed.

Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE

Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. Subjects who have been retreated after such a reaction may be allowed after discussion with the Simcha Medical Monitor

History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Subjects that have received radiation therapy to the lung that is \>30Gy within 6 months of the first dose of study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT04787042) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

I cannot determine the primary medical condition from the provided information. The study title only mentions "ST-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (ST-067, Obinutuzumab, and pembrolizumab) rather than medical conditions. The brief summary field appears to be incomplete. Without information about the actual disease or condition being treated, I cannot extract a patient-facing medical condition. Treatment Options in Tampa, FL

If you're searching for i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. treatment options in Tampa, FL, this clinical trial (NCT04787042) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. clinical trials near you to find additional studies recruiting in your area.

Expert Care in Tampa

IRB Approved

No-Cost Care

Apply for This Tampa Location

Why Participate?

Simple Process

Who Can Participate